Hydroxychloroquine-induced Stevens-Johnson syndrome in COVID-19: a rare case report
Hydroxychloroquine-induced Stevens-Johnson syndrome in COVID-19: a rare case report
复制标题
DOI：
10.1093/omcr/omaa042
复制
发表时间：
2020-06-01
影响因子：
0.5
通讯作者：
Razavi, Alireza
中科院分区：
文献类型：
--
作者：
Davoodi, Lotfollah;Jafarpour, Hamed;Razavi, Alireza
名为2019年冠状病毒病（COVID-19）的国际呼吸道疾病爆发于2019年12月，已影响超过80万人。自限性呼吸道受累、严重肺炎、多器官衰竭和死亡是COVID-19的表现。到目前为止，还没有针对COVID-19感染的特殊治疗药物。其中一种药物包括抗疟药羟氯喹（HCQ），最近有报道称，这种药物可能用于缩短COVID-19症状的持续时间，减少感染的炎症反应，减轻肺炎的恶化，并提高肺部成像结果。与所有药物一样，HCQ也有副作用，可能发生在COVID-19患者身上。在这里，我们报告了一例42岁女性的病例，她出现发热和干咳，患有COVID-19，2天后出现了从上肢远端开始并迅速累及全身的炎性红斑性斑丘疹。
The international outbreak of respiratory illness termed coronavirus disease 2019 (COVID-19) began in December 2019 that has affected >0.8 million individuals. Self-limiting respiratory tract involvement, severe pneumonia, multiorgan failure and death are the spectrum of COVID-19. To date, there are no especial therapeutic agents for COVID-19 infections. One such medication includes the antimalarial hydroxychloroquine (HCQ), which recently reported as a possible therapy for shortening the duration of COVID-19 symptoms, reducing inflammatory reactions to infection, impairing the exacerbation of pneumonia and boosting lung imaging findings. Like all medications, HCQ has side effects and may occur in COVID-19 patients. Here, we report on the case of a 42-year-old woman, presented with fever and dry cough, who had COVID-19 and 2 days later presented with a pruritic erythematous maculopapular rash, which started from the distal of upper extremities and rapidly, involved the entire body.